TransMedics Group (NASDAQ:TMDX) Coverage Initiated by Analysts at UBS Group

Equities research analysts at UBS Group initiated coverage on shares of TransMedics Group (NASDAQ:TMDX) in a research report issued on Tuesday. The firm set a “neutral” rating and a $80.00 price target on the stock. UBS Group’s target price points to a potential upside of 7.70% from the company’s previous close.

A number of other equities analysts have also recently commented on the stock. Needham & Company LLC cut their price target on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. TD Cowen reissued a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research note on Wednesday, July 1st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a research note on Tuesday, June 30th. Finally, Stifel Nicolaus increased their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, June 18th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $129.55.

TransMedics Group Stock Up 2.8%

TMDX opened at $74.28 on Tuesday. The company has a fifty day moving average price of $71.85 and a 200-day moving average price of $102.27. The firm has a market capitalization of $2.57 billion, a P/E ratio of 16.88 and a beta of 1.89. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. TransMedics Group has a one year low of $60.10 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The business had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter last year, the business posted $0.70 EPS. Equities research analysts expect that TransMedics Group will post 1.88 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

A number of institutional investors have recently made changes to their positions in TMDX. Goldman Sachs Group Inc. grew its holdings in shares of TransMedics Group by 50.1% in the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock worth $117,506,000 after purchasing an additional 322,353 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of TransMedics Group by 54.2% in the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after purchasing an additional 223,409 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of TransMedics Group by 100.5% in the fourth quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock worth $52,713,000 after purchasing an additional 217,180 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after purchasing an additional 171,810 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after purchasing an additional 113,817 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.